These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 15851138)

  • 1. Are there alternatives to mortality as an endpoint in clinical trials of atrial fibrillation?
    Wyse DG
    Heart Rhythm; 2004 Jul; 1(2 Suppl):B41-4, discussion B44. PubMed ID: 15851138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alternative endpoints for mortality in studies of patients with atrial fibrillation: the AFFIRM study experience.
    Wyse DG; Slee A; Epstein AE; Gersh BJ; Rocco T; Vidaillet H; Volgman A; Weiss R; Shemanski L; Greene HL;
    Heart Rhythm; 2004 Nov; 1(5):531-7. PubMed ID: 15851214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of amiodarone in patients with atrial fibrillation with and without left ventricular dysfunction: a pooled analysis of AFFIRM and AF-CHF trials.
    Cadrin-Tourigny J; Wyse DG; Roy D; Blondeau L; Levesque S; Talajic M; Andrade JG; Dubuc M; Thibault B; Guerra PG; Macle L; Rivard L; Khairy P
    J Cardiovasc Electrophysiol; 2014 Dec; 25(12):1306-13. PubMed ID: 25181386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does intensity of rate-control influence outcome in atrial fibrillation? An analysis of pooled data from the RACE and AFFIRM studies.
    Van Gelder IC; Wyse DG; Chandler ML; Cooper HA; Olshansky B; Hagens VE; Crijns HJ;
    Europace; 2006 Nov; 8(11):935-42. PubMed ID: 16973686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heart rate and adverse outcomes in patients with atrial fibrillation: A combined AFFIRM and AF-CHF substudy.
    Andrade JG; Roy D; Wyse DG; Tardif JC; Talajic M; Leduc H; Tourigny JC; Shohoudi A; Dubuc M; Rivard L; Guerra PG; Thibault B; Dyrda K; Macle L; Khairy P
    Heart Rhythm; 2016 Jan; 13(1):54-61. PubMed ID: 26299677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular hospitalization as a surrogate endpoint for mortality in studies of atrial fibrillation: report from the Stockholm Cohort Study of Atrial Fibrillation.
    Friberg L; Rosenqvist M
    Europace; 2011 May; 13(5):626-33. PubMed ID: 21296777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AFFIRM and RACE trials: implications for the management of atrial fibrillation.
    Blackshear JL; Safford RE; ;
    Card Electrophysiol Rev; 2003 Dec; 7(4):366-9. PubMed ID: 15071255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of cause-specific mortality in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study.
    Steinberg JS; Sadaniantz A; Kron J; Krahn A; Denny DM; Daubert J; Campbell WB; Havranek E; Murray K; Olshansky B; O'Neill G; Sami M; Schmidt S; Storm R; Zabalgoitia M; Miller J; Chandler M; Nasco EM; Greene HL
    Circulation; 2004 Apr; 109(16):1973-80. PubMed ID: 15051639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overview of endpoints in atrial fibrillation studies.
    Wyse DG
    Heart Rhythm; 2004 Jul; 1(2 Suppl):B3-7, discussion B7. PubMed ID: 15851133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Occurrence and characteristics of stroke events in the Atrial Fibrillation Follow-up Investigation of Sinus Rhythm Management (AFFIRM) study.
    Sherman DG; Kim SG; Boop BS; Corley SD; Dimarco JP; Hart RG; Haywood LJ; Hoyte K; Kaufman ES; Kim MH; Nasco E; Waldo AL;
    Arch Intern Med; 2005 May; 165(10):1185-91. PubMed ID: 15911734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rhythm control in atrial fibrillation: endpoints for device-based trials.
    Gillis AM
    Heart Rhythm; 2004 Jul; 1(2 Suppl):B52-7, discussion B57. PubMed ID: 15851140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).
    Washam JB; Stevens SR; Lokhnygina Y; Halperin JL; Breithardt G; Singer DE; Mahaffey KW; Hankey GJ; Berkowitz SD; Nessel CC; Fox KA; Califf RM; Piccini JP; Patel MR;
    Lancet; 2015 Jun; 385(9985):2363-70. PubMed ID: 25749644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Burden, timing, and relationship of cardiovascular hospitalization to mortality among Medicare beneficiaries with newly diagnosed atrial fibrillation.
    Turakhia MP; Solomon MD; Jhaveri M; Davis P; Eber MR; Conrad R; Summers N; Lakdawalla D
    Am Heart J; 2013 Sep; 166(3):573-80. PubMed ID: 24016509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is health-related quality of life a predictor of hospitalization or mortality among women or men with atrial fibrillation?
    Chapa DW; Akintade B; Schron E; Friedmann E; Thomas SA
    J Cardiovasc Nurs; 2014; 29(6):555-64. PubMed ID: 24165699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quality of life in atrial fibrillation: the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study.
    Jenkins LS; Brodsky M; Schron E; Chung M; Rocco T; Lader E; Constantine M; Sheppard R; Holmes D; Mateski D; Floden L; Prasun M; Greene HL; Shemanski L
    Am Heart J; 2005 Jan; 149(1):112-20. PubMed ID: 15660042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implantable cardioverter-defibrillator therapy and risk of congestive heart failure or death in MADIT II patients with atrial fibrillation.
    Zareba W; Steinberg JS; McNitt S; Daubert JP; Piotrowicz K; Moss AJ;
    Heart Rhythm; 2006 Jun; 3(6):631-7. PubMed ID: 16731460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program.
    Olsson LG; Swedberg K; Ducharme A; Granger CB; Michelson EL; McMurray JJ; Puu M; Yusuf S; Pfeffer MA;
    J Am Coll Cardiol; 2006 May; 47(10):1997-2004. PubMed ID: 16697316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Digoxin in patients with permanent atrial fibrillation: data from the RACE II study.
    Mulder BA; Van Veldhuisen DJ; Crijns HJ; Tijssen JG; Hillege HL; Alings M; Rienstra M; Van den Berg MP; Van Gelder IC;
    Heart Rhythm; 2014 Sep; 11(9):1543-50. PubMed ID: 24924587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does health-related quality of life predict hospitalization or mortality in patients with atrial fibrillation?
    Schron E; Friedmann E; Thomas SA
    J Cardiovasc Electrophysiol; 2014 Jan; 25(1):23-8. PubMed ID: 24102986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atrial fibrillation: what have recent trials taught us regarding pharmacologic management of rate and rhythm control?
    Reiffel JA
    Pacing Clin Electrophysiol; 2011 Feb; 34(2):247-59. PubMed ID: 21091736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.